42-27 Mark Socinski Named Executive Medical Director at Florida Hospital Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In Brief

Mark Socinski Named Executive Medical Director at Florida Hospital Cancer Institute

MARK SOCINSKI was named executive medical director of the Florida Hospital Cancer Institute. He will oversee the coordination of clinical cancer services for the Florida Hospital network. He will also be a member of the institute’s Thoracic Oncology Program.

Socinski comes from the University of Pittsburgh Medical Center, where he served as professor of medicine and cardiovascular surgery; director of the Lung Cancer Section for the Division of Hematology and Oncology; co-director of the Lung Cancer Center of Excellence; and co-director of the Lung Cancer Program. Prior to joining UPMC, Socinski served as professor of medicine at the University of North Carolina. His research focuses on clinical trials in thoracic cancers.

THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY named 10 members as ASTRO Fellows, in the 10th year that the designation has been awarded. The 2016 class will be recognized at an awards ceremony during ASTRO’s annual meeting Sept. 25-28, in Boston.

Fellows have been an active or emeritus member of ASTRO for at least 15 years, giving the equivalent of 10 years of service to ASTRO through committee service and similar activities. With the addition of the 2016 class, a total of 269 ASTRO members have received the FASTRO designation since 2006.

“The individuals in this class of ASTRO Fellows demonstrate both talent and commitment across multiple aspects of radiation oncology, particularly in clinical care, research, service and education,” said ASTRO Chair Bruce Minsky. “As is the case for our other fellows, the clinicians and researchers in the 2016 cohort show a clear dedication to improving patients’ lives and advancing our field, especially through service to ASTRO and its initiatives.”

The new ASTRO Fellows are:

H. Joseph Barthold, Beth Israel Deaconess Hospital-Plymouth

Jennifer Bellon, Dana-Farber Cancer Institute and Harvard Medical School

Laura Dawson, Princess Margaret Cancer Centre, University of Toronto

Theodore DeWeese, Johns Hopkins University

Shalom Kalnicki, Albert Einstein College of Medicine Montefiore Medical Center

Nancy Mendenhall, University of Florida, Gainesville

William Mendenhall, University of Florida, Gainesville

Todd Pawlicki, University of California San Diego

Timothy Solberg, University of California San Francisco

John Suh, Cleveland Clinic

THE UNIVERSITY OF MICHIGAN Comprehensive Cancer Center and Trovagene Inc. initiated a collaborative research program focused on the Trovera KRAS ctDNA liquid biopsy test in pancreatic cancer.

“KRAS gene mutations occur in over 90 percent of pancreatic carcinomas. There is an urgent need for targeted therapies and a precision diagnostic test to identify who would benefit from these therapies,” said Diane Simeone, director of the Pancreatic Cancer Center at the University of Michigan Comprehensive Cancer Center. “As part of this research collaboration, Trovagene’s ctDNA urine and blood tests will be utilized as noninvasive diagnostic tools to enable early detection and rapid monitoring of patient response to therapy. The Trovagene assay will allow us to quickly test multiple therapies to determine which one will be most effective in treating an individual patient’s tumor.”